Intrinsic Imaging Announces Acquisition, Accelerating Global Expansion as a Leading Imaging Core Lab

BOSTON, Mass. — September 1, 2026 — Intrinsic Imaging, a globally recognized leader in medical imaging core lab services and artificial intelligence (AI)-enabled imaging trials, today announced its acquisition by Acquired Imaging from WCG Clinical, Inc. This acquisition marks a significant new chapter in Intrinsic Imaging's 16-year history as the company continues to advance its imaging capabilities and support clinical trials worldwide. Financial terms of the transaction were not disclosed.

Founded in 2010, Intrinsic Imaging provides comprehensive imaging core lab services for Phase I–IV clinical trials and Class I, II, and III medical device studies. The company is also a recognized leader in AI validation studies designed to evaluate AI algorithms, computer-aided detection (CAD) systems, and advanced medical imaging software.

With more than 1,000 board-certified and fellowship-trained physicians in its network, and supporting over 4,000 imaging centers in 64 countries, Intrinsic Imaging provides subspecialty expertise across all major therapeutic areas, including oncology, cardiology, central nervous system disorders, gastroenterology, musculoskeletal conditions, and ophthalmology.

Intrinsic Imaging has the most sophisticated and comprehensive quality management system in the imaging core lab industry. Certified by the British Standards Institute (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for the provision of imaging core lab services for clinical trials.

"This acquisition marks an exciting new chapter for Intrinsic Imaging and strengthens our ability to deliver even greater value to our clients," said Todd Joron, BSc, MBA, Co-Founder, President and CEO of Intrinsic Imaging. "We will continue to build on the trust our clients place in us by combining scientific and medical expertise, advanced technology, and rigorous execution to reduce imaging complexity, protect the integrity of clinical trial endpoints, and advance important therapies and medical technologies."

"As clinical trials become increasingly complex and data-intensive, medical imaging continues to play a critical role in evaluating therapeutic efficacy and safety," said Heekwan Lee, BSc, Vice President, Imaging Operations, Intrinsic Imaging. "Intrinsic Imaging addresses this complexity by combining advanced imaging technologies with rigorous operational processes and expert physician oversight, enabling our clients to improve trial efficiency and data quality while generating reliable, scientifically robust imaging data to support critical clinical development decisions."

Looking ahead, Intrinsic Imaging will continue to invest in and expand its medical imaging core lab capabilities, technology platform, global physician network, and AI expertise. These investments will further strengthen the company's ability to provide high-quality, efficient, and scientifically rigorous imaging core lab services to clinical trial sponsors worldwide.

For more information, visit IntrinsicImaging.com.